Canadian Court Issues Injunction Ordering AlCana to Return Tekmira Documents, Information | GenomeWeb

By Doug Macron

Tekmira Pharmaceuticals this week scored a victory in its technology-misappropriation lawsuit against Alnylam Pharmaceuticals and AlCana Technologies, announcing that a British Columbia court has granted its request for an injunction ordering AlCana to return confidential documents and materials to Tekmira in advance of a trial.

The injunction also orders AlCana to disclose “every person and corporation to whom the information was provided or communicated,” Tekmira said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.

The Wall Street Journal reports that Walgreens didn't fully vet Theranos before entering partnership.

Jeremy Berg is to be the next editor in chief of Science magazine.

Regeneron Pharmaceuticals is to be the new sponsor of the prestigious high school Science Talent Search competition, according to the New York Times.